FDA approach to evaluation of pathogen reduction technology

被引：45

作者：

Epstein, JS ^{[1
]}

Vostal, JG ^{[1
]}

机构：

[1] FDA, Ctr Biol Evaluat & Res, Off Blood Res & Review, Rockville, MD USA

来源：

TRANSFUSION | 2003年 / 43卷 / 10期

关键词：

D O I：

10.1046/j.1537-2995.2003.00584.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1347 / 1350

页数：4

共 13 条

[1] Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms [J].

Brecher, ME ;

Means, N ;

Jere, CS ;

Heath, D ;

Rothenberg, S ;

Stutzman, LC .

TRANSFUSION, 2001, 41 (04) :477-482

[2]

BRECHER ME, 2003, BLOOD THERAPIES MED, V2, P49

[3] Current and emerging infectious risks of blood transfusions [J].

Busch, MP ;

Kleinman, SH ;

Nemo, GJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (08) :959-962

[4] Bacterial contamination and transfusion safety: experience in the United States [J].

Dodd, RY .

TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2003, 10 (01) :6-9

[5]

*FDA, 1999, WORKSH BACT CONT PLA

[6]

*FDA, 2002, WORKSH SAF EFF METH

[7]

FDA, 2002, CARC STUD PROT SUBM

[8]

*FDA, 1998, WORKSH EV IN VIV EFF

[9]

*FDA, 1997, SBI TEST CARC PHARM

[10]

*FDA, 1999, FDA DRAFT GUID PLAT

← 1 2 →